Compagnie Lombard Odier S Cm A Enlivex Therapeutics Ltd. Transaction History

Compagnie Lombard Odier S Cm A

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$1.29 - $2.92 $83,850 - $189,800	-65,000 Closed	0 $0
Q1 2023 May 01, 2023	BUY	$3.41 - $4.55 $51,150 - $68,250	15,000 Added 30.0%	65,000 $236,000
Q1 2022 Apr 27, 2022	BUY	$4.92 - $6.66 $34,440 - $46,620	7,000 Added 16.28%	50,000 $279,000
Q4 2021 Feb 09, 2022	BUY	$5.81 - $9.73 $46,480 - $77,840	8,000 Added 22.86%	43,000 $247,000
Q3 2021 Oct 28, 2021	BUY	$7.43 - $13.86 $74,300 - $138,600	10,000 Added 40.0%	35,000 $353,000
Q1 2021 Apr 23, 2021	BUY	$9.26 - $24.0 $231,500 - $600,000	25,000 New	25,000 $267,000

2.1M

16.1K

3.4K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $28.9M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.